OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
Thomas A Prohaska, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 3, pp. 406-411
Open Access | Times Cited: 30
Thomas A Prohaska, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 3, pp. 406-411
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Brian A. Bergmark, Nicholas Marston, Thomas A Prohaska, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1770-1780
Closed Access | Times Cited: 77
Brian A. Bergmark, Nicholas Marston, Thomas A Prohaska, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1770-1780
Closed Access | Times Cited: 77
VLDL Biogenesis and Secretion: It Takes a Village
Willemien van Zwol, Bart van de Sluis, Henry N. Ginsberg, et al.
Circulation Research (2024) Vol. 134, Iss. 2, pp. 226-244
Open Access | Times Cited: 21
Willemien van Zwol, Bart van de Sluis, Henry N. Ginsberg, et al.
Circulation Research (2024) Vol. 134, Iss. 2, pp. 226-244
Open Access | Times Cited: 21
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Brian Tomlinson, Qianyan Wu, Yi-ming Zhong, et al.
Journal of Lipid and Atherosclerosis (2024) Vol. 13, Iss. 1, pp. 2-2
Open Access | Times Cited: 18
Brian Tomlinson, Qianyan Wu, Yi-ming Zhong, et al.
Journal of Lipid and Atherosclerosis (2024) Vol. 13, Iss. 1, pp. 2-2
Open Access | Times Cited: 18
Updates in Drug Treatment of Severe Hypertriglyceridemia
Ioanna Gouni‐Berthold, Jonas Andersson Schwarz, Heiner K. Berthold
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 10, pp. 701-709
Open Access | Times Cited: 35
Ioanna Gouni‐Berthold, Jonas Andersson Schwarz, Heiner K. Berthold
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 10, pp. 701-709
Open Access | Times Cited: 35
APOC3 siRNA and ASO therapy for dyslipidemia
Jasmine Chebli, Miriam Larouche, Daniel Gaudet
Current Opinion in Endocrinology Diabetes and Obesity (2024) Vol. 31, Iss. 2, pp. 70-77
Closed Access | Times Cited: 15
Jasmine Chebli, Miriam Larouche, Daniel Gaudet
Current Opinion in Endocrinology Diabetes and Obesity (2024) Vol. 31, Iss. 2, pp. 70-77
Closed Access | Times Cited: 15
The chylomicron saga: time to focus on postprandial metabolism
Alejandro Gugliucci
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 13
Alejandro Gugliucci
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 13
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Dick C. Chan, Gerald F. Watts
Current Opinion in Lipidology (2024) Vol. 35, Iss. 3, pp. 101-109
Closed Access | Times Cited: 9
Dick C. Chan, Gerald F. Watts
Current Opinion in Lipidology (2024) Vol. 35, Iss. 3, pp. 101-109
Closed Access | Times Cited: 9
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access | Times Cited: 1
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access | Times Cited: 1
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Chris J. Packard, Angela Pirillo, Sotirios Tsimikas, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 18, pp. 2843-2857
Open Access | Times Cited: 21
Chris J. Packard, Angela Pirillo, Sotirios Tsimikas, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 18, pp. 2843-2857
Open Access | Times Cited: 21
Cholesterol transport and beyond: Illuminating the versatile functions of HDL apolipoproteins through structural insights and functional implications
Aishwarya Sudam Bhale, Olivier Meilhac, Christian Lefebvre d’Hellencourt, et al.
BioFactors (2024) Vol. 50, Iss. 5, pp. 922-956
Open Access | Times Cited: 6
Aishwarya Sudam Bhale, Olivier Meilhac, Christian Lefebvre d’Hellencourt, et al.
BioFactors (2024) Vol. 50, Iss. 5, pp. 922-956
Open Access | Times Cited: 6
Etiology and emerging treatments for familial chylomicronemia syndrome
Catherine M. Spagnuolo, Robert A. Hegele
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 4, pp. 299-306
Open Access | Times Cited: 6
Catherine M. Spagnuolo, Robert A. Hegele
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 4, pp. 299-306
Open Access | Times Cited: 6
Research Progress on Residual Cholesterol in Cardiovascular Diseases
璐 姚
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 812-817
Closed Access
璐 姚
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 812-817
Closed Access
Design and Rationale of the CORE –TIMI 72a and CORE2 –TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia
Nicholas Marston, Brian A. Bergmark, Veronica J. Alexander, et al.
American Heart Journal (2025)
Closed Access
Nicholas Marston, Brian A. Bergmark, Veronica J. Alexander, et al.
American Heart Journal (2025)
Closed Access
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Brian Tomlinson, Paul Chan
Expert Opinion on Pharmacotherapy (2025), pp. 1-11
Closed Access
Brian Tomlinson, Paul Chan
Expert Opinion on Pharmacotherapy (2025), pp. 1-11
Closed Access
Trans-ancestral rare variant association study with machine learning-based phenotyping for metabolic dysfunction-associated steatotic liver disease
Robert Chen, Ben Omega Petrazzini, Áine Duffy, et al.
Genome biology (2025) Vol. 26, Iss. 1
Open Access
Robert Chen, Ben Omega Petrazzini, Áine Duffy, et al.
Genome biology (2025) Vol. 26, Iss. 1
Open Access
Novel Therapeutics for Familial Chylomicronemia Syndrome
Maria Cristina de Oliveira Izar, Francisco Antônio Helfenstein Fonseca
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Open Access
Maria Cristina de Oliveira Izar, Francisco Antônio Helfenstein Fonseca
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Open Access
Target Populations for Novel Triglyceride-Lowering Therapies
Ask T. Nordestgaard, Anne Tybjærg‐Hansen, Hank Mansbach, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 19, pp. 1876-1897
Closed Access
Ask T. Nordestgaard, Anne Tybjærg‐Hansen, Hank Mansbach, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 19, pp. 1876-1897
Closed Access
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial
André Zimerman, Stephen D. Wiviott, Jeong‐Gun Park, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 10, pp. 1216-1223
Open Access | Times Cited: 3
André Zimerman, Stephen D. Wiviott, Jeong‐Gun Park, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 10, pp. 1216-1223
Open Access | Times Cited: 3
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Benjamin Nilsson Wadström, Anders Berg Wulff, Kasper Mønsted Pedersen, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 11, pp. 795-803
Closed Access | Times Cited: 7
Benjamin Nilsson Wadström, Anders Berg Wulff, Kasper Mønsted Pedersen, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 11, pp. 795-803
Closed Access | Times Cited: 7
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
Naif Saad ALGhasab, Federica Fogacci, Ashot Avagimyan, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 2
Naif Saad ALGhasab, Federica Fogacci, Ashot Avagimyan, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 2
Liver-specific actions of GH and IGF1 that protect against MASLD
Rhonda D. Kineman, Mercedes Del Rio-Moreno, David J. Waxman
Nature Reviews Endocrinology (2024)
Closed Access | Times Cited: 2
Rhonda D. Kineman, Mercedes Del Rio-Moreno, David J. Waxman
Nature Reviews Endocrinology (2024)
Closed Access | Times Cited: 2
Present and Future of Dyslipidaemia Treatment—A Review
Iveta Merćep, Andro Vujević, Dominik Strikić, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 5839-5839
Open Access | Times Cited: 6
Iveta Merćep, Andro Vujević, Dominik Strikić, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 5839-5839
Open Access | Times Cited: 6
The Role of RNA Splicing in Liver Function and Disease: A Focus on Metabolic Dysfunction-Associated Steatotic Liver Disease
Dorota Kamińska
Genes (2024) Vol. 15, Iss. 9, pp. 1181-1181
Open Access | Times Cited: 1
Dorota Kamińska
Genes (2024) Vol. 15, Iss. 9, pp. 1181-1181
Open Access | Times Cited: 1
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Brian Tomlinson
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Brian Tomlinson
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
